(Q33729078)

English

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Edouard J Trabulsi

4

object named as

Edouard J Trabulsi

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Elizabeth R Plimack

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Jean H Hoffman-Censits

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Rosalia Viterbo

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Eric A Ross

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Richard E Greenberg

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

David Y T Chen

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Costas D Lallas

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Yu-Ning Wong

9

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Jianqing Lin

10

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Alexander Kutikov

11

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Efrat Dotan

12

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Timothy A Brennan

13

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Norma Palma

14

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Essel Dulaimi

15

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Reza Mehrazin

16

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Stephen A Boorjian

17

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

William Kevin Kelly

18

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Robert G Uzzo

19

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Gary R Hudes

20

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

12 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1895-1901

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

Genome sequencing identifies a basis for everolimus sensitivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

Telomere length measurement by a novel monochrome multiplex quantitative PCR method

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

21 June 2018

The Clavien-Dindo classification of surgical complications: five-year experience.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

30 October 2018

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4050203

30 October 2018

Treatment of Muscle Invasive Bladder Cancer: Evidence From the National Cancer Database, 2003 to 2007

1 reference

https://pubmed.ncbi.nlm.nih.gov/24821881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24821881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24821881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kuhn's paradigms: are those closest to treating bladder cancer the last to appreciate the paradigm shift?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24821881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systematic assessment of complications and outcome of radical cystectomy undertaken with curative intent in patients with comorbidity and over 75 years of age

1 reference

https://pubmed.ncbi.nlm.nih.gov/24821881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology

1 reference

https://pubmed.ncbi.nlm.nih.gov/24821881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/24821881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24821881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

1 reference

https://pubmed.ncbi.nlm.nih.gov/24821881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC

1 reference

https://pubmed.ncbi.nlm.nih.gov/24821881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists

1 reference

https://pubmed.ncbi.nlm.nih.gov/24821881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2013.53.2465

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33729078&oldid=1981053649"